Point-of-Care Molecular Diagnostics Market by Product & Service (Assays, Instruments, Software), Technology (RT-PCR, INAAT), Sample Type (Blood, Urine), Application (STD, HAI, Hepatitis, Cancer), and End User (Hospitals, Clinics) - Global Forecast to 2030

1 INTRODUCTION 32 1.1 STUDY OBJECTIVES 32 1.2 MARKET DEFINITION 32 1.3 STUDY SCOPE 33 1.3.1 MARKETS COVERED & REGIONAL SCOPE 33 1.3.2 INCLUSIONS & EXCLUSIONS 34 1.3.3 YEARS CONSIDERED 35 1.3.4 CURRENCY CONSIDERED 35 1.4 KEY STAKEHOLDERS 35 1.5 SUMMARY OF CHANGES 36 2 RESEARCH METHODOLOGY 37 2.1 RESEARCH DATA 37 2.2 RESEARCH APPROACH 37 2.2.1 SECONDARY DATA 38 2.2.1.1 Key secondary sources 38 2.2.1.2 Key data from secondary sources 39 2.2.2 PRIMARY DATA 40 2.2.2.1 Primary sources 40 2.2.2.2 Key data from primary sources 41 2.2.2.3 Key industry insights 42 2.2.2.4 Breakdown of primary interviews 42 2.3 MARKET SIZE ESTIMATION 43 2.3.1 BOTTOM-UP APPROACH 44 2.3.1.1 Approach 1: Company revenue estimation approach 44 2.3.1.2 Approach 2: Presentations of companies and primary interviews 44 2.3.1.3 Growth forecast 45 2.3.1.4 CAGR projections 45 2.3.2 TOP-DOWN APPROACH 46 2.4 MARKET BREAKDOWN & DATA TRIANGULATION 47 2.5 MARKET SHARE ASSESSMENT 48 2.6 RESEARCH ASSUMPTIONS 49 2.6.1 PARAMETRIC ASSUMPTIONS 49 2.7 RESEARCH LIMITATIONS 49 2.8 RISK ASSESSMENT 50 3 EXECUTIVE SUMMARY 51   4 PREMIUM INSIGHTS 56 4.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET OVERVIEW 56 4.2 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 57 4.3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 57 4.4 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION) 58 4.5 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 58 4.6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 59 4.7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59 5 MARKET OVERVIEW 60 5.1 INTRODUCTION 60 5.2 MARKET DYNAMICS 60 5.2.1 DRIVERS 61 5.2.1.1 Increasing prevalence of infectious diseases and cancer 61 5.2.1.2 Increasing focus on decentralized diagnostics and subsequent rise in R&D funding 62 5.2.1.3 Growing awareness associated with early disease diagnosis 63 5.2.1.4 Increasing use of POC diagnostic tests 64 5.2.2 RESTRAINTS 64 5.2.2.1 Unfavorable reimbursements 64 5.2.2.2 High capital investments and low cost-benefit ratio 65 5.2.3 OPPORTUNITIES 65 5.2.3.1 Growth opportunities in emerging economies 65 5.2.4 CHALLENGES 66 5.2.4.1 Stringent regulatory guidelines that impact product commercialization 66 5.2.4.2 Introduction of alternative technologies 67 5.3 PRICING ANALYSIS 67 5.3.1 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023−2025 67 5.3.2 AVERAGE PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023−2025 68 5.3.3 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023−2025 68 5.4 PATENT ANALYSIS 70 5.4.1 LIST OF KEY PATENTS 71 5.5 VALUE CHAIN ANALYSIS 72 5.6 SUPPLY CHAIN ANALYSIS 73 5.7 TRADE ANALYSIS 74 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS 74 5.7.2 IMPORT DATA (HS CODE 3822) 75 5.7.3 EXPORT DATA (HS CODE 3822) 75 5.8 ECOSYSTEM ANALYSIS 76 5.8.1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 76 5.9 PORTER’S FIVE FORCES ANALYSIS 77 5.9.1 THREAT OF NEW ENTRANTS 78 5.9.2 BARGAINING POWER OF SUPPLIERS 78 5.9.3 THREAT OF SUBSTITUTES 78 5.9.4 BARGAINING POWER OF BUYERS 78 5.9.5 INTENSITY OF COMPETITIVE RIVALRY 79 5.10 REGULATORY LANDSCAPE 79 5.10.1 REGULATORY FRAMEWORK 79 5.10.1.1 North America 79 5.10.1.1.1 US 79 5.10.1.1.2 Canada 79 5.10.1.2 EUROPE 79 5.10.1.2.1 Germany 80 5.10.1.2.2 UK 80 5.10.1.2.3 France 81 5.10.1.2.4 Italy 81 5.10.1.3 Asia Pacific 81 5.10.1.3.1 China 81 5.10.1.3.2 Japan 81 5.10.1.3.3 India 82 5.10.1.4 Latin America 82 5.10.1.4.1 Brazil 82 5.10.1.4.2 Mexico 83 5.10.1.5 Middle East 83 5.10.1.5.1 Africa 83 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 5.11 TECHNOLOGY ANALYSIS 86 5.11.1 KEY TECHNOLOGIES 86 5.11.1.1 RT-PCR 86 5.11.2 COMPLEMENTARY TECHNOLOGIES 86 5.11.2.1 INAAT (Isolated Nucleic Acid Amplification Technology) 86 5.11.3 ADJACENT TECHNOLOGIES 87 5.11.3.1 CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) 87 5.12 KEY CONFERENCES & EVENTS, 2025–2026 87   5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 88 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 89 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 89 5.14.2 BUYING CRITERIA 90 5.15 INVESTMENT & FUNDING SCENARIO 91 5.16 CASE STUDY ANALYSIS 91 5.16.1 CASE STUDY 1: RAPID POINT OF CARE PCR TESTING STREAMLINES EMERGENCY CARE FOR HOSPITAL IN GERMANY 91 5.16.2 CASE STUDY 2: IMPLEMENTATION OF RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT 92 5.16.3 CASE STUDY 3: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTION 92 5.17 IMPACT OF AI/GENERATIVE AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 93 5.17.1 INTRODUCTION 93 5.17.2 MARKET POTENTIAL OF AI 93 5.17.3 AI-USE CASES 94 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE 94 5.17.5 FUTURE OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 95 5.18 TRUMP TARIFF IMPACT ON POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 95 5.18.1 INTRODUCTION 95 5.18.2 KEY TARIFF RATES 95 5.18.3 PRICE IMPACT ANALYSIS 96 5.18.4 IMPACT ON COUNTRY/REGION 96 5.18.4.1 North America 96 5.18.4.2 Europe 97 5.18.4.3 Asia Pacific 97 5.18.5 IMPACT ON END-USE INDUSTRIES 97 5.18.5.1 Physicians’ Offices/Clinics 97 5.18.5.2 Hospitals 97 5.18.5.3 Research Institutes 98 6 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 99 6.1 INTRODUCTION 100 6.2 ASSAYS & KITS 100 6.2.1 RECURRENT PURCHASE TO PROPEL MARKET 100 6.3 INSTRUMENTS & ANALYZERS 104 6.3.1 INCREASING ADOPTION OF ADVANCED POC TECHNOLOGIES TO DRIVE MARKET 104 6.4 SOFTWARE & SERVICES 107 6.4.1 UTILIZATION OF SOLUTIONS FOR ENHANCED USER EXPERIENCE TO SUPPORT MARKET GROWTH 107 7 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY 111 7.1 INTRODUCTION 112 7.2 RT-PCR 112 7.2.1 HIGH SENSITIVITY AND SPECIFICITY TO BOOST DEMAND 112 7.3 INAAT 116 7.3.1 COST-BENEFITS AND RAPID AMPLIFICATION ABILITIES TO PROPEL MARKET 116 7.4 OTHER TECHNOLOGIES 118 8 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE 122 8.1 INTRODUCTION 123 8.2 BLOOD SAMPLES 123 8.2.1 ABILITY TO SUPPORT RAPID DETECTION FOR SEVERAL DISEASES TO PROPEL MARKET 123 8.3 URINE SAMPLES 126 8.3.1 NON-INVASIVE NATURE AND DETECTION OF LOW BIOMARKER CONCENTRATION TO BOOST DEMAND 126 8.4 OTHER SAMPLE TYPES 129 9 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION 133 9.1 INTRODUCTION 134 9.2 RESPIRATORY DISEASES 134 9.2.1 RISING INCIDENCE OF INFLUENZA AND RSV TO DRIVE MARKET 134 9.3 SEXUALLY TRANSMITTED DISEASES 138 9.3.1 RISING PREVALENCE OF HPV AND HIV TO DRIVE MARKET 138 9.4 HOSPITAL-ACQUIRED INFECTIONS 142 9.4.1 GROWING FOCUS ON TARGETED CLINICAL THERAPY FOR REDUCTION IN HAIS TO FUEL MARKET 142 9.5 CANCER 145 9.5.1 INCREASING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO DRIVE MARKET 145 9.6 HEPATITIS 148 9.6.1 INCREASING PREVALENCE AMONG HIGH-RISK SUBGROUP POPULATIONS TO PROPEL MARKET 148 9.7 GASTROINTESTINAL DISORDERS 151 9.7.1 RISING INCIDENCE OF IBS TO SUPPORT MARKET GROWTH 151 9.8 OTHER APPLICATIONS 154 10 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER 158 10.1 INTRODUCTION 159 10.2 HOSPITALS 159 10.2.1 CAPABILITY TO PURCHASE ADVANCED DIAGNOSTIC EQUIPMENT AND ABILITY TO SUPPORT HIGH PATIENT FOOTFALL TO PROPEL MARKET 159 10.2.1.1 Sepsis 163 10.2.1.1.1 Rising requirement for rapid diagnosis & treatment to fuel uptake 163 10.2.1.2 Gastroenteritis 163 10.2.1.2.1 Increasing admissions to critical care units and rising focus on molecular tools for diagnosis to fuel uptake 163 10.2.1.3 Meningoencephalitis 164 10.2.1.3.1 Initialization of targeted treatment due to high mortality risk to fuel market 164 10.2.1.4 Other diseases 164 10.3 PHYSICIANS’ OFFICES/CLINICS 165 10.3.1 RAPID RESULTS AND INDIVIDUALIZED CARE TO FUEL MARKET 165 10.4 RESEARCH INSTITUTES 167 10.4.1 INCREASING FOCUS ON GENOMICS & PROTEOMICS RESEARCH TO BOOST DEMAND 167 10.5 OTHER END USERS 170 11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION 173 11.1 INTRODUCTION 174 11.2 NORTH AMERICA 174 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 177 11.2.2 US 180 11.2.2.1 High healthcare expenditure for advanced molecular diagnostic technologies to drive market 180 11.2.3 CANADA 183 11.2.3.1 Favorable government initiatives for early disease diagnosis awareness to fuel market 183 11.3 EUROPE 186 11.3.1 EUROPE: MACROECONOMIC OUTLOOK 187 11.3.2 GERMANY 189 11.3.2.1 Universal healthcare coverage and favorable growth for decentralized care settings to fuel market 189 11.3.3 UK 192 11.3.3.1 Rising prevalence of STIs to boost demand 192 11.3.4 FRANCE 196 11.3.4.1 High disease burden of infectious diseases and cancer to drive market 196 11.3.5 ITALY 198 11.3.5.1 Rising demand for high-precision diagnostic tools to support market growth 198 11.3.6 SPAIN 201 11.3.6.1 Rising incidence of respiratory illnesses and HIV to boost demand 201 11.3.7 REST OF EUROPE 203   11.4 ASIA PACIFIC 206 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 208 11.4.2 CHINA 210 11.4.2.1 Increasing incidence of influenza and epidemics to propel market 210 11.4.3 JAPAN 214 11.4.3.1 Growing access to advanced & affordable healthcare services to fuel market 214 11.4.4 INDIA 217 11.4.4.1 Expanding healthcare access and increasing prevalence of HIV to propel market 217 11.4.5 REST OF ASIA PACIFIC 219 11.5 LATIN AMERICA 222 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 223 11.5.2 BRAZIL 226 11.5.2.1 High incidence of hepatitis to support market uptake 226 11.5.3 MEXICO 228 11.5.3.1 Rising cases of TB and HAIs to fuel market 228 11.5.4 REST OF LATIN AMERICA 231 11.6 MIDDLE EAST & AFRICA 234 11.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 235 11.6.2 KINGDOM OF SAUDI ARABIA (KSA) 238 11.6.2.1 Improvements in healthcare infrastructure to drive market 238 11.6.3 UNITED ARAB EMIRATES (UAE) 240 11.6.3.1 Rising technological advancements in molecular diagnostics to fuel market 240 11.6.4 REST OF MIDDLE EAST & AFRICA 243 12 COMPETITIVE LANDSCAPE 246 12.1 INTRODUCTION 246 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 246 12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 246 12.3 REVENUE SHARE ANALYSIS, 2022−2024 248 12.4 MARKET SHARE ANALYSIS, 2024 249 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 251 12.5.1 STARS 251 12.5.2 EMERGING LEADERS 251 12.5.3 PERVASIVE PLAYERS 251 12.5.4 PARTICIPANTS 252 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 253 12.5.5.1 Company footprint 253 12.5.5.2 Region footprint 254 12.5.5.3 Product & service footprint 254 12.5.5.4 Technology footprint 255 12.5.5.5 Application footprint 255 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 256 12.6.1 PROGRESSIVE COMPANIES 256 12.6.2 RESPONSIVE COMPANIES 256 12.6.3 DYNAMIC COMPANIES 256 12.6.4 STARTING BLOCKS 256 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 258 12.6.5.1 Detailed list of key startups/SMEs 258 12.6.5.2 Competitive benchmarking of key emerging players/startups (1/2) 258 12.6.5.3 Competitive benchmarking of key startups/SMEs (2/2) 259 12.7 COMPANY VALUATION & FINANCIAL METRICS 259 12.7.1 FINANCIAL METRICS 259 12.7.2 COMPANY VALUATION 260 12.8 BRAND/PRODUCT COMPARISON 261 12.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS 261 12.9 COMPETITIVE SCENARIO 262 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 262 12.9.2 DEALS 263 12.9.3 EXPANSIONS 264 13 COMPANY PROFILES 265 13.1 KEY PLAYERS 265 13.1.1 DANAHER CORPORATION 265 13.1.1.1 Business overview 265 13.1.1.2 Products/Services offered 266 13.1.1.3 Recent developments 267 13.1.1.3.1 Product/Service launches & approvals 267 13.1.1.3.2 Deals 269 13.1.1.3.3 Expansions 269 13.1.1.4 MnM view 270 13.1.1.4.1 Key strengths 270 13.1.1.4.2 Strategic choices 270 13.1.1.4.3 Weaknesses & competitive threats 270 13.1.2 BIOMÉRIEUX 271 13.1.2.1 Business overview 271 13.1.2.2 Products/Services offered 272 13.1.2.3 Recent developments 273 13.1.2.3.1 Product/Service launches & approvals 273 13.1.2.3.2 Deals 273   13.1.2.4 MnM view 274 13.1.2.4.1 Key strengths 274 13.1.2.4.2 Strategic choices 274 13.1.2.4.3 Weaknesses & competitive threats 274 13.1.3 F. HOFFMANN-LA ROCHE LTD. 275 13.1.3.1 Business overview 275 13.1.3.2 Products/Services offered 276 13.1.3.3 Recent developments 277 13.1.3.3.1 Products/Services launches & approvals 277 13.1.3.3.2 Deals 278 13.1.3.3.3 Expansions 278 13.1.3.4 MnM view 279 13.1.3.4.1 Key strengths 279 13.1.3.4.2 Strategic choices 279 13.1.3.4.3 Weaknesses & competitive threats 279 13.1.4 ABBOTT 280 13.1.4.1 Business overview 280 13.1.4.2 Products/Services offered 281 13.1.4.3 Recent developments 282 13.1.4.3.1 Deals 282 13.1.4.4 MnM view 282 13.1.4.4.1 Key strengths 282 13.1.4.4.2 Strategic choices 283 13.1.4.4.3 Weaknesses & competitive threats 283 13.1.5 QIAGEN N.V. 284 13.1.5.1 Business overview 284 13.1.5.2 Products/Services offered 285 13.1.5.3 Recent developments 286 13.1.5.3.1 Product launches & approvals 286 13.1.5.3.2 Deals 287 13.1.5.3.3 Expansions 288 13.1.5.4 MnM view 288 13.1.5.4.1 Key strengths 288 13.1.5.4.2 Strategic choices 288 13.1.5.4.3 Weaknesses & competitive threats 288 13.1.6 QUIDELORTHO CORPORATION 289 13.1.6.1 Business overview 289 13.1.6.2 Products/Services offered 290 13.1.6.3 Recent developments 292 13.1.6.3.1 Product/Service launches & approvals 292 13.1.6.3.2 Deals 292 13.1.6.3.3 Expansions 293 13.1.7 CO-DIAGNOSTICS, INC. 294 13.1.7.1 Business overview 294 13.1.7.2 Products/Services offered 295 13.1.7.3 Recent developments 295 13.1.7.3.1 Deals 295 13.1.7.3.2 Expansions 296 13.1.8 BIOCARTIS 297 13.1.8.1 Business overview 297 13.1.8.2 Products/Services offered 299 13.1.8.3 Recent developments 299 13.1.8.3.1 Product/Service launches & approvals 299 13.1.8.3.2 Deals 300 13.1.9 SD BIOSENSOR, INC. 301 13.1.9.1 Business overview 301 13.1.9.2 Products/Services offered 302 13.1.9.3 Recent developments 303 13.1.9.3.1 Product/Service launches 303 13.1.9.3.2 Deals 303 13.1.9.3.3 Other developments 304 13.1.10 GENEDRIVE PLC 305 13.1.10.1 Business overview 305 13.1.10.2 Products/Services offered 306 13.2 OTHER PLAYERS 307 13.2.1 BINX HEALTH, INC. 307 13.2.2 MOLBIO DIAGNOSTICS LIMITED 308 13.2.3 OPGEN, INC. 310 13.2.4 GENOMADIX 310 13.2.5 VISBY MEDICAL, INC. 311 13.2.6 QUANTUMDX GROUP LTD. 311 13.2.7 DETECTACHEM 312 13.2.8 LABSYSTEMS DIAGNOSTICS OY 312 13.2.9 AKONNI BIOSYSTEMS, INC. 313 13.2.10 UBIQUITOME LIMITED 314 13.2.11 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD. 314 13.2.12 NUCLEIN, LLC 315 13.2.13 GENES2ME 316 13.2.14 AXXIN 317 13.2.15 HUWEL LIFESCIENCES 318   14 APPENDIX 319 14.1 DISCUSSION GUIDE 319 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 324 14.3 CUSTOMIZATION OPTIONS 326 14.4 RELATED REPORTS 326 14.5 AUTHOR DETAILS 327

TABLE 1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS 34 TABLE 2 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES 41 TABLE 3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 50 TABLE 4 REGIONAL HIV DATA, 2024 62 TABLE 5 AVERAGE SELLING PRICING TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, 2023–2025 67 TABLE 6 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC ASSAYS & KITS, BY KEY PLAYER, 2023–2025 68 TABLE 7 AVERAGE SELLING PRICE TREND OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS, BY REGION, 2023–2025 68 TABLE 8 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS 71 TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 75 TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD MILLION) 75 TABLE 11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 76 TABLE 12 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 78 TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE 80 TABLE 14 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 82 TABLE 17 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 20 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 88 TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS (%) 90 TABLE 22 KEY BUYING CRITERIA FOR POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS 90 TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & USE CASE 94 TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 95 TABLE 25 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 100 TABLE 26 KEY ASSAYS & KITS CURRENTLY AVAILABLE 101 TABLE 27 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 28 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 29 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 30 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 31 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 32 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR ASSAYS & KITS, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 33 KEY INSTRUMENTS & ANALYZERS CURRENTLY AVAILABLE 104 TABLE 34 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 35 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 36 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 37 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 38 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 39 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS & ANALYZERS, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 40 KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE 108 TABLE 41 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 42 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 43 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 44 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 45 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 46 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 47 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 112 TABLE 48 KEY RT-PCR-BASED PRODUCTS CURRENTLY AVAILABLE 113 TABLE 49 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 50 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 51 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 52 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 53 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 54 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 55 KEY INAAT-BASED PRODUCTS CURRENTLY AVAILABLE 116 TABLE 56 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 57 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 58 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 59 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 60 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 61 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 62 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 119 TABLE 63 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 64 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 65 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 66 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 67 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 68 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 123 TABLE 69 KEY BLOOD SAMPLE TYPE-BASED PRODUCTS CURRENTLY AVAILABLE 124 TABLE 70 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2023–2030 (USD MILLION) 124 TABLE 71 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 72 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 73 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 74 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 75 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 76 KEY URINE SAMPLE-BASED PRODUCTS CURRENTLY AVAILABLE 127 TABLE 77 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 78 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 79 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 80 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 81 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 82 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 83 KEY OTHER SAMPLE TYPE-BASED PRODUCTS CURRENTLY AVAILABLE 130 TABLE 84 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 85 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 86 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 87 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 88 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 89 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 90 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 134 TABLE 91 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR RESPIRATORY DISEASES CURRENTLY AVAILABLE 135 TABLE 92 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 93 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 94 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 95 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 96 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 97 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 98 NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023–2030 (IN MILLIONS) 138 TABLE 99 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR SEXUALLY TRANSMITTED DISEASES CURRENTLY AVAILABLE 139 TABLE 100 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 101 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 102 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 103 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 104 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 105 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 106 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023–2030 (USD MILLION) 143 TABLE 107 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 108 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 109 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 110 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 111 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 112 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 113 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 114 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 115 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 116 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 117 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 118 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR HEPATITIS CURRENTLY AVAILABLE 149 TABLE 119 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 120 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 121 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 122 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 123 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 124 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 125 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR GASTROINTESTINAL DISORDERS CURRENTLY AVAILABLE 152 TABLE 126 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 152 TABLE 127 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 128 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 129 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 130 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 131 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 132 KEY POC MOLECULAR DIAGNOSTIC PRODUCTS FOR OTHER APPLICATIONS CURRENTLY AVAILABLE 155 TABLE 133 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 155 TABLE 134 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 135 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 136 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 137 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 138 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 139 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 159 TABLE 140 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 160 TABLE 141 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 161 TABLE 142 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 143 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 144 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 145 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 146 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 147 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 148 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 149 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 150 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 151 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 152 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR PHYSICIANS’ OFFICES/CLINICS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 153 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 168 TABLE 154 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 155 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 156 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 157 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 158 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 159 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 160 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 161 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 162 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 163 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 164 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 165 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 166 NORTH AMERICA: MACROECONOMIC INDICATORS 176 TABLE 167 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 168 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 177 TABLE 169 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 178 TABLE 170 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 178 TABLE 171 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 179 TABLE 172 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 179 TABLE 173 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 181 TABLE 174 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 181 TABLE 175 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 182 TABLE 176 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 182 TABLE 177 US: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 183 TABLE 178 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 184 TABLE 179 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 184 TABLE 180 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 185 TABLE 181 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 185 TABLE 182 CANADA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 186 TABLE 183 EUROPE: MACROECONOMIC INDICATORS 187 TABLE 184 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 185 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 188 TABLE 186 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 188 TABLE 187 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 188 TABLE 188 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 189 TABLE 189 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 189 TABLE 190 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 191 TABLE 191 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 191 TABLE 192 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 191 TABLE 193 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 192 TABLE 194 GERMANY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 192 TABLE 195 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 194 TABLE 196 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 194 TABLE 197 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 194 TABLE 198 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 195 TABLE 199 UK: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 195 TABLE 200 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 196 TABLE 201 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 197 TABLE 202 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 197 TABLE 203 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198 TABLE 204 FRANCE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 198 TABLE 205 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 199 TABLE 206 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 199 TABLE 207 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 200 TABLE 208 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 200 TABLE 209 ITALY: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 201 TABLE 210 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 202 TABLE 211 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 202 TABLE 212 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 202 TABLE 213 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 203 TABLE 214 SPAIN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 203 TABLE 215 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 204 TABLE 216 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 204 TABLE 217 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 205 TABLE 218 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 205 TABLE 219 REST OF EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 220 ASIA PACIFIC: MACROECONOMIC INDICATORS 207 TABLE 221 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 208 TABLE 222 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 208 TABLE 223 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 209 TABLE 224 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 209 TABLE 225 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 210 TABLE 226 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 210 TABLE 227 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 211 TABLE 228 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 212 TABLE 229 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 212 TABLE 230 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 213 TABLE 231 CHINA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 232 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 215 TABLE 233 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 215 TABLE 234 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 215 TABLE 235 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 216 TABLE 236 JAPAN: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 216 TABLE 237 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 218 TABLE 238 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 218 TABLE 239 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 218 TABLE 240 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 219 TABLE 241 INDIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 219 TABLE 242 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 220 TABLE 243 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 221 TABLE 244 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 221 TABLE 245 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 222 TABLE 246 REST OF ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 222 TABLE 247 LATIN AMERICA: MACROECONOMIC INDICATORS 223 TABLE 248 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 224 TABLE 249 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 224 TABLE 250 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 224 TABLE 251 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 225 TABLE 252 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 225 TABLE 253 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 254 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 227 TABLE 255 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 227 TABLE 256 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 227 TABLE 257 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 228 TABLE 258 BRAZIL: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 228 TABLE 259 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 229 TABLE 260 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 229 TABLE 261 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 230 TABLE 262 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 263 MEXICO: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 231 TABLE 264 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 232 TABLE 265 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 232 TABLE 266 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 233 TABLE 267 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 233 TABLE 268 REST OF LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 269 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 235 TABLE 270 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 236 TABLE 271 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 236 TABLE 272 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 236 TABLE 273 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 237 TABLE 274 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 237 TABLE 275 MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 238 TABLE 276 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 239 TABLE 277 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 239 TABLE 278 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 239 TABLE 279 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 240 TABLE 280 KINGDOM OF SAUDI ARABIA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 240 TABLE 281 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 241 TABLE 282 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 241 TABLE 283 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 242 TABLE 284 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 242 TABLE 285 UNITED ARAB EMIRATES: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 243 TABLE 286 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023–2030 (USD MILLION) 244 TABLE 287 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 244 TABLE 288 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 244 TABLE 289 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 245 TABLE 290 REST OF MIDDLE EAST & AFRICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2023–2030 (USD MILLION) 245 TABLE 291 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, JANUARY 2021−JULY 2025 246 TABLE 292 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DEGREE OF COMPETITION 250 TABLE 293 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: REGION FOOTPRINT 254 TABLE 294 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT 254 TABLE 295 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 255 TABLE 296 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: APPLICATION FOOTPRINT 255 TABLE 297 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 258 TABLE 298 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS (1/2) 258 TABLE 299 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 259 TABLE 300 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 262 TABLE 301 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DEALS, JANUARY 2021–JULY 2025 263 TABLE 302 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–JULY 2025 264 TABLE 303 DANAHER CORPORATION: COMPANY OVERVIEW 265 TABLE 304 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 266 TABLE 305 DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 267 TABLE 306 DANAHER CORPORATION: DEALS, JANUARY 2021–JULY 2025 269 TABLE 307 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2025 269 TABLE 308 BIOMÉRIEUX: COMPANY OVERVIEW 271 TABLE 309 BIOMÉRIEUX: PRODUCTS/SERVICES OFFERED 272 TABLE 310 BIOMÉRIEUX: PRODUCT/SERVICE APPROVALS, JANUARY 2021–JULY 2025 273 TABLE 311 BIOMÉRIEUX: DEALS, JANUARY 2021–JULY 2025 273 TABLE 312 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 275 TABLE 313 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 276 TABLE 314 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 277 TABLE 315 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–JULY 2025 278 TABLE 316 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021–JULY 2025 278 TABLE 317 ABBOTT: COMPANY OVERVIEW 280 TABLE 318 ABBOTT PRODUCTS/SERVICES OFFERED 281 TABLE 319 ABBOTT: DEALS, JANUARY 2021–JULY 2025 282 TABLE 320 QIAGEN N.V.: COMPANY OVERVIEW 284 TABLE 321 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED 285 TABLE 322 QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 286 TABLE 323 QIAGEN N.V.: DEALS, JANUARY 2021–JULY 2025 287 TABLE 324 QIAGEN N.V.: EXPANSIONS, JANUARY 2021–JULY 2025 288 TABLE 325 QUIDELORTHO CORPORATION: COMPANY OVERVIEW 289 TABLE 326 QUIDELORTHO CORPORATION: PRODUCTS/SERVICES OFFERED 290 TABLE 327 QUIDELORTHO CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 292 TABLE 328 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–JULY 2025 292 TABLE 329 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–JULY 2025 293 TABLE 330 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW 294 TABLE 331 CO-DIAGNOSTICS, INC.: PRODUCTS/SERVICES OFFERED 295 TABLE 332 CO-DIAGNOSTICS, INC.: DEALS, JANUARY 2021–JULY 2025 295 TABLE 333 CO-DIAGNOSTICS, INC.: EXPANSIONS, JANUARY 2021–JULY 2025 296 TABLE 334 BIOCARTIS: COMPANY OVERVIEW 297 TABLE 335 BIOCARTIS: PRODUCTS/SERVICES OFFERED 299 TABLE 336 BIOCARTIS: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–JULY 2025 299 TABLE 337 BIOCARTIS: DEALS, JANUARY 2021–JULY 2025 300 TABLE 338 SD BIOSENSOR, INC.: BUSINESS OVERVIEW 301 TABLE 339 SD BIOSENSOR, INC.: PRODUCTS/SERVICES OFFERED 302 TABLE 340 SD BIOSENSOR, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JULY 2025 303 TABLE 341 SD BIOSENSOR, INC.: DEALS, JANUARY 2021–JULY 2025 303 TABLE 342 SD BIOSENSOR, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2025 304 TABLE 343 GENEDRIVE PLC: COMPANY OVERVIEW 305 TABLE 344 GENEDRIVE PLC: PRODUCTS/SERVICES OFFERED 306 TABLE 345 BINX HEALTH, INC.: COMPANY OVERVIEW 307 TABLE 346 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW 308 TABLE 347 OPGEN, INC.: COMPANY OVERVIEW 310 TABLE 348 GENOMADIX: COMPANY OVERVIEW 310 TABLE 349 VISBY MEDICAL, INC.: COMPANY OVERVIEW 311 TABLE 350 QUANTUMDX GROUP LTD.: COMPANY OVERVIEW 311 TABLE 351 DETECTACHEM: COMPANY OVERVIEW 312 TABLE 352 LABSYSTEMS DIAGNOSTICS OY: COMPANY OVERVIEW 312 TABLE 353 AKONNI BIOSYSTEMS, INC.: COMPANY OVERVIEW 313 TABLE 354 UBIQUITOME LIMITED: COMPANY OVERVIEW 314 TABLE 355 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.: COMPANY OVERVIEW 314 TABLE 356 NUCLEIN, LLC: COMPANY OVERVIEW 315 TABLE 357 GENES2ME: COMPANY OVERVIEW 316 TABLE 358 AXXIN: COMPANY OVERVIEW 317 TABLE 359 HUWEL LIFESCIENCES: COMPANY OVERVIEW 318 FIGURE 1 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE 33 FIGURE 2 YEARS CONSIDERED 35 FIGURE 3 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY 37 FIGURE 4 PRIMARY SOURCES 40 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 42 FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 43 FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 44 FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 45 FIGURE 9 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TOP-DOWN APPROACH 46 FIGURE 10 DATA TRIANGULATION METHODOLOGY 48 FIGURE 11 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS 49 FIGURE 12 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION) 51 FIGURE 13 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 52 FIGURE 14 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION) 52 FIGURE 15 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 53 FIGURE 16 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 54 FIGURE 17 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 55 FIGURE 18 INCREASING ADVANCEMENTS IN MOLECULAR DIAGNOSTICS TECHNOLOGIES TO PROPEL MARKET 56 FIGURE 19 ASSAYS & KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 57 FIGURE 20 RT-PCR SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 57 FIGURE 21 OTHER SAMPLE TYPES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 58 FIGURE 22 RESPIRATORY DISEASES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 58 FIGURE 23 HOSPITALS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 59 FIGURE 24 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 59 FIGURE 25 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60 FIGURE 26 PATENT ANALYSIS FOR POINT OF CARE MOLECULAR DIAGNOSTICS (JANUARY 2014–DECEMBER 2024) 70 FIGURE 27 VALUE CHAIN ANALYSIS OF POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES 72 FIGURE 28 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 74 FIGURE 29 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 76 FIGURE 30 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 77 FIGURE 31 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89 FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS 89 FIGURE 33 KEY BUYING CRITERIA FOR POINT OF CARE MOLECULAR DIAGNOSTIC PRODUCTS 90 FIGURE 34 NUMBER OF DEALS & FUNDING ACTIVITIES IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 91 FIGURE 35 MARKET POTENTIAL OF AI IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET 93 FIGURE 36 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 176 FIGURE 37 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SNAPSHOT 207 FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, 2022–2024 248 FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS IN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET (2024) 249 FIGURE 40 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 252 FIGURE 41 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY FOOTPRINT 253 FIGURE 42 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 257 FIGURE 43 EV/EBITDA OF KEY VENDORS 259 FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 260 FIGURE 45 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS 261 FIGURE 46 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 266 FIGURE 47 BIOMÉRIEUX: COMPANY SNAPSHOT (2024) 272 FIGURE 48 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 276 FIGURE 49 ABBOTT: COMPANY SNAPSHOT (2024) 281 FIGURE 50 QIAGEN N.V.: COMPANY SNAPSHOT (2024) 285 FIGURE 51 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024) 290 FIGURE 52 CO-DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2024) 294 FIGURE 53 BIOCARTIS: COMPANY SNAPSHOT (2022) 298 FIGURE 54 SD BIOSENSOR, INC.: COMPANY SNAPSHOT (2024) 301 FIGURE 55 GENEDRIVE PLC: COMPANY SNAPSHOT (2024) 305